Compare MXCT & BSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MXCT | BSL |
|---|---|---|
| Founded | 1999 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.8M | 167.7M |
| IPO Year | 2021 | 2010 |
| Metric | MXCT | BSL |
|---|---|---|
| Price | $1.56 | $12.85 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $4.11 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 42.1K |
| Earning Date | 11-10-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.55% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $33,026,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $15.53 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.64 | $12.45 |
| 52 Week High | $1.81 | $13.99 |
| Indicator | MXCT | BSL |
|---|---|---|
| Relative Strength Index (RSI) | 63.38 | 44.31 |
| Support Level | $1.17 | $12.74 |
| Resistance Level | N/A | $13.01 |
| Average True Range (ATR) | 0.12 | 0.07 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 75.12 | 35.48 |
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
Blackstone Senior Floating Rate Term Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. The fund also invests in second-lien loans and high yield bonds and employs financial leverage which may increase the risk to the Fund.